Adis Journal Podcasts

Adis
  • 0.0 (0)
  • LIFE SCIENCES
  • UPDATED MONTHLY

Listen to podcasts with key opinion leaders in multiple therapy areas, discussing hot topics including topic overviews, expert opinions and conference overviews. Brought to you by the Adis Journals Group, part of Springer Nature. The primary audience for these podcasts are healthcare professionals, and are published and citable through the journals.

  1. First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options—A Podcast

    JAN 28

    First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options—A Podcast

    In this podcast, Eric K. Singhi from the University of Texas MD Anderson Cancer Center, Houston, TX, USA, and Eric S. Nadler from the Baylor University Medical Center, Dallas, TX, USA discuss the available treatment options for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) and focus on the efficacy and safety of first-line treatments and sequencing strategies. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-025-01192-y. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

    19 min

  2. 12/17/2025

    Social Determinants of Health in Metastatic Breast Cancer Care: A Podcast Exploring Challenges and Opportunities in the

    This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00406-7. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

    20 min
  3. Burgeoning Non-Muscle Invasive Bladder Cancer Space: AUA 2025 Clinical Trials Presented (Doctor/Patient Podcast)

    12/16/2025

    Burgeoning Non-Muscle Invasive Bladder Cancer Space: AUA 2025 Clinical Trials Presented (Doctor/Patient Podcast)

    In this plain language podcast, the authors discuss highlights from the American Urological Association (AUA) Annual Meeting 2025. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of bladder cancer. This podcast is intended to broaden the reach of complex data and insights from AUA 2025 to a broader audience, including non-specialists, helping enable better informed treatment decisions between patients and healthcare professionals. The authors introduce the current treatment landscape for patients and discuss four clinical trials focusing on patients with bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC). This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00409-4. All conflicts of interest can be found online. This podcast is primarily intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

    21 min
  4. The Role of Comorbidities in Treatment Decision-Making across the Spectrum of Prostate Cancer: A Podcast

    12/08/2025

    The Role of Comorbidities in Treatment Decision-Making across the Spectrum of Prostate Cancer: A Podcast

    Managing prostate cancer today means balancing cancer control with overall health and wellbeing. This episode explores how chronic conditions, frailty, and quality-of-life considerations shape treatment choices from localised to advanced disease. Authors discuss why survival data has shifted the rationale for radical interventions, the complexities introduced by systemic therapy, and why assessing physiological age matters more than chronological age. Discover how comprehensive geriatric assessment supports personalised care, and how holistic, multidisciplinary decision-making can align treatment with life expectancy, patient preference, and independence. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00407-6. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

    31 min
  5. Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025: A Podcast

    11/27/2025

    Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025: A Podcast

    In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of prostate cancer. This podcast is intended to broaden the reach of complex data and insights from ASCO 2025 to a broader audience, including non-specialists, helping enable better-informed treatment decisions between patients and healthcare professionals. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00403-w. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. This podcast is intended for medical professionals.

    33 min

  6. 11/24/2025

    Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast

    This podcast is published open access in Pulmonary Therapy and is fully citeable. You can access the original published podcast article through the Pulmonary Therapy website and by using this link: https://link.springer.com/article/10.1007/s41030-025-00330-1. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

    30 min

  7. 11/21/2025

    Real-World Perspectives on Switching Patients With Multiple Sclerosis From Anti-CD20 Therapy to Cladribine Tablets From

    This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the XX website and by using this link: https://link.springer.com/article/10.1007/s12325-025-03391-5. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

    34 min
  8. Treatment in R/M-SCCHN in the Year 2025 - Standard and Considerations for am Individualized Treatment

    11/21/2025

    Treatment in R/M-SCCHN in the Year 2025 - Standard and Considerations for am Individualized Treatment

    A Podcast Discussion on Medical Treatment in R/M-SCCHN in the Year 2025—Standard and Considerations for an Individualized Treatment In this podcast, speakers Dr Konrad Klinghammer and Dr Philipp Ivanyi discuss the general principles of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), with a focus on key phase 3 clinical trials such as KEYNOTE-048 and EXTREME. The strengths and limitations of these studies are evaluated, and in the context of additional phase 2 trials, considerations are made regarding individualised treatment strategies based on patient-specific characteristics when selecting first-line therapy. Second-line treatment decisions should be based on the mode of action used in the first-line setting —pending further clinical trials to establish optimal treatment sequencing. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00396-6. This podcast has been developed through educational funding from Merck Healthcare Germany GmbH, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The authors were selected by the journal, and the content of the podcast was developed independently by the authors and the journal Editors. The Rapid Service was funded by this educational funding also. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

    47 min
See All (110)

About

Listen to podcasts with key opinion leaders in multiple therapy areas, discussing hot topics including topic overviews, expert opinions and conference overviews. Brought to you by the Adis Journals Group, part of Springer Nature. The primary audience for these podcasts are healthcare professionals, and are published and citable through the journals.

Information

  • Creator
    Adis
  • Years Active
    2020 - 2026
  • Episodes
    110
  • Rating
    Clean
  • Copyright
    © Springer Healthcare, part of Springer Nature
  • Show Website
    Adis Journal Podcasts